Skip to Content

Data from the BRCAAway Study Confirms Better PFS & Efficacy with a Combination of Olaparib + Abiraterone Prednisone

In this MEDtalk, Dr. Maha Hussain presents data from the BRCAAway study. The study demonstrates that combining abiraterone & prednisone with olaparib improves efficacy and progression-free survival in metastatic castration-resistant prostate cancer patients with BRCA1/2 or ATM mutation.

Maha H. A. Hussain

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top